Prostate stem cell antigen (PSCA) is a recently de®ned homologue of the Thy-1/Ly-6 family of glycosylphosphatidylinositol (GPI)-anchored cell surface antigens. PSCA mRNA is expressed in the basal cells of normal prostate and in more than 80% of prostate cancers. The purpose of the present study was to examine PSCA protein expression in clinical specimens of human prostate cancer. Five monoclonal antibodies were raised against a PSCA-GST fusion protein and screened for their ability to recognize PSCA on the cell surface of human prostate cancer cells. Immunohistochemical analysis of PSCA expression was performed on paran-embedded sections from 25 normal tissues, 112 primary prostate cancers and nine prostate cancers metastatic to bone. The level of PSCA expression in prostate tumors was quanti®ed and compared with expression in adjacent normal glands. The antibodies detect PSCA expression on the cell surface of normal and malignant prostate cells and distinguish three extracellular epitopes on PSCA. Prostate and transitional epithelium reacted strongly with PSCA. PSCA staining was also seen in placental trophoblasts, renal collecting ducts and neuroendocrine cells in the stomach and colon. All other normal tissues tested were negative. PSCA protein expression was identi®ed in 105/112 (94%) primary prostate tumors and 9/9 (100%) bone metastases. The level of PSCA expression increased with higher Gleason score (P=0.016), higher tumor stage (P=0.010) and progression to androgen-independence (P=0.021). Intense, homogeneous staining was seen in all nine bone metastases. PSCA is a cell surface protein with limited expression in extraprostatic normal tissues. PSCA expression correlates with tumor stage, grade and androgen independence and may have prognostic utility. Because expression on the surface of prostate cancer cells increases with tumor progression, PSCA may be a useful molecular target in advanced prostate cancer.
Introduction
Prostate cancer is the most common cancer diagnosis and the second leading cause of cancer-related death in American men (Lalani et al., 1997) . Although great progress has been made in the diagnosis and management of localized disease, there continues to be a need for new diagnostic markers that can better discriminate between indolent and aggressive variants of prostate cancer. There also continues to be a need for the identi®cation and characterization of potential new therapeutic targets on prostate cancer cells. Current immunological approaches to the control and treatment of recurrent and metastatic prostate cancer have been limited by a lack of prostate and cancer-speci®c target antigens. Although a number of prostate-speci®c genes have been identi®ed (i.e. prostate speci®c antigen, prostatic acid phosphatase, glandular kallikrein 2), the majority of these are secreted proteins not ideally suited for many immunological strategies, such as in vivo targeting by monoclonal antibodies. Prostate-speci®c membrane antigen (PSMA) is the only cell surface antigen yet reported which has relative prostate-speci®city Murphy et al., 1998a; Silver et al., 1997) . Monoclonal antibodies that recognize the extracellular domain of PSMA have recently been reported and are currently being evaluated for use in prostate cancer diagnosis and treatment (Liu et al., 1997; Murphy et al., 1998b) .
We recently reported the identi®cation of prostate stem cell antigen (PSCA) . PSCA is a 123 amino acid glycoprotein with 30% identity to stem cell antigen 2 (Sca 2), a cell surface marker of immature thymic lymphocytes (Antica et al., 1997; Classon and Coverdale, 1994) . Like Sca-2, PSCA is attached to the cell membrane by a GPI anchor which can be cleaved by treatment with a GPI-speci®c phospholipase. Among 16 normal tissues examined, PSCA mRNA was expressed predominantly in prostate and placenta. mRNA in situ hybridization localized PSCA expression in normal prostate to the basal cell epithelium, the putative stem cell compartment of prostatic epithelium, suggesting that PSCA may be a marker of prostate stem/progenitor cells. PSCA mRNA was also detected in greater than 80% of primary prostate cancers by in situ analysis. In addition, mRNA expression in cancers often appeared to be stronger than in adjacent normal glands, raising the possibility that PSCA may be overexpressed in some prostate tumors and might have some cancer speci®city. PSCA maps to chromosome 8q24.2, a region of genetic gain/ampli®cation in a large percentage of advanced prostate cancers (Cher et al., 1994) . These initial results supported PSCA as a potential target for prostate cancer diagnosis and therapy.
In order to examine PSCA protein expression in vivo and validate it as a potential target for prostate cancer diagnosis and/or therapy, we have isolated and characterized a series of monoclonal antibodies directed against PSCA. These antibodies detect PSCA on the cell surface of nonpermeabilized cells, con®rm-ing the cell surface localization of PSCA. Immunohistochemical analysis of a large series of primary tumors demonstrates that PSCA expression increases in more advanced stages and grades of prostate cancer. In addition, PSCA is expressed strongly in all cases of prostate cancer bone metastases examined. These results support PSCA as a potential diagnostic and/or therapeutic target in prostate cancer.
Results
Monoclonal antibodies directed against PSCA stain the cell surface of prostate cancer cells and recognize a minimum of three epitopes on PSCA Monoclonal antibodies (mAbs) were raised against a PSCA-GST fusion protein lacking both the amino and carboxyl terminal signal sequences of PSCA. Positive fusions were selected by ELISA using the PSCA-GST fusion protein and GST alone. Out of 400 hybridomas screened, 28 recognized the PSCA-GST fusion but not GST alone. These fusions were screened secondarily bȳ ow cytometry of nonpermeabilized 293T cells transfected with PSCA and mock transfected 293T cells. Secondary screening by FACS was done in order to select clones capable of recognizing PSCA on the cell surface, hypothesizing that these might later become useful for in vivo targeting applications. Seven positive fusions were identi®ed in this manner, of which ®ve (mAbs 4A10, 1G8, 3E6, 3C5 and 2H9) were subcloned and puri®ed.
In order to determine the ability of mAbs 2H9, 3E6, 1G8, 4A10 and 3C5 to recognize PSCA speci®cally on the cell surface of prostate cancer cells, LNCaP cells transfected with PSCA (LNCaP-PSCA) and LAPC-9 cells were examined by¯ow cytometry and indirect immuno¯uorescence. LAPC-9 is a prostate cancer xenograft which expresses PSCA mRNA, whereas the LNCaP prostate cancer cell line does not express endogenous PSCA. All ®ve mAbs were able to detect PSCA on the cell surface of nonpermeabilized LNCaP-PSCA and/or LAPC-9 cells by¯ow cytometry ( Figure 1a ) and immuno¯uores-cence (Figure 1b) . mAb 2H9 stained the cell surface of LAPC-9 but not LNCaP-PSCA, suggesting that the epitope recognized by this mAb may be obscured in the latter cells. All mAbs produced a punctate staining pattern on the cell surface, which was most pronounced with mAbs 3E6, 3C5 and 4A10 ( Figure  1b ). This pattern may re¯ect aggregation or clustering of PSCA to regions of the cell surface. Mocktransfected LNCaP and LNCaP transfected with a neomycin-alone containing vector (LNCaP-neo) were both negative in both analyses. These results demonstrate that all ®ve mAbs react with PSCA on the cell surface of intact prostate cancer cells.
The location on PSCA of the epitopes recognized by the ®ve mAbs was determined by immunoblot analysis using three truncated PSCA-GST fusion proteins. mABs 4A10, 2H9 and 3C5 recognize an epitope residing within the amino-terminal portion of PSCA (amino acids 21 ± 50); mAb 1G8 recognizes an epitope in the middle of PSCA (amino acids 46 ± 85); and mAb 3E6 reacts with the carboxyl-terminal portion of PSCA (amino acids 85 ± 99). These results demonstrate that the ®ve mAbs recognize at least three distinct epitopes on PSCA.
Immunohistochemical staining of PSCA in a normal prostate PSCA mRNA localizes to a subset of basal cells in a normal prostate, suggesting that PSCA may be a cell surface marker for prostate stem/progenitor cells . In order to test the possibility that PSCA protein may be a marker of basal cells, PSCA expression was examined immunohistochemically in paran-embedded sections of normal prostate. mAbs 1G8 and 2H9 stained the cytoplasm of both basal and secretory cells, while mAb 3E6 reacted predominantly with basal cells (Figure 2 ). Atrophic glands, which express basal cell cytokeratins, stained strongly with all three mAbs (O'Malley et al., 1990) . In addition, prostatic neuroendocrine cells were positive (con®rmed by double-staining for chromogranin) (data not shown). mAbs 3C5 and 4A10 gave strong background staining and/or nonspeci®c nuclear staining in paran sections and were not used further. Therefore, although PSCA mRNA is detected speci®cally in basal cells, PSCA protein is present in both epithelial cell layers (i.e. basal and secretory) and the neuroendocrine cells of the prostate.
Immunohistochemical analysis of normal tissues
Our initial studies indicated that PSCA expression in men was largely prostate-speci®c, with low levels of detectable mRNA in kidney and small intestine. PSCA mRNA was also detected in placenta. The prostatespeci®city of PSCA protein expression was tested by immunohistochemical staining of 25 tissues using mAb 1G8 (see Table 1 ). As predicted by the RNA analysis, placenta was positive with all mAbs tested, with cytoplasmic staining detected in the trophoblasts (Figure 3 ). In kidney, weak staining was detected in the collecting ducts and some tubules, but not in glomeruli (Figure 3 ). Transitional epithelium of the bladder, which had not been examined previously at the mRNA level, was also positive (Figure 3 ). In addition, there was staining of colonic and gastric neuroendocrine cells (con®rmed by doublestaining with chromogranin) (Figure 3 ). Expression of PSCA by the stomach and bladder were con®rmed by Northern blot analysis (data not shown). These results demonstrate that PSCA expression in men is restricted to prostate and a small set of nonprostatic tissues, most prominent of which are bladder and neuroendocrine cells of the stomach and colon. and 4A10. Negative controls included irrelevant isotype antibody and LNCaP cells transfected with control vector, all of which showed no staining even after prolonged exposures (not shown). mAb 2H9 also did not stain these cells, as described in the text, and is not shown Figure 2 Immunohistochemical staining of a normal prostate. Paran-embedded sections of normal prostate were immunostained with anti-PSCA mAbs 1G8 and 3E6. mAb 1G8 reacts equally with both basal (arrowhead) and secretory (arrow) cells, whereas mAb 3E6 stains basal cells (arrowhead) more strongly than secretory cells (arrow). Speci®city of staining was tested by preincubation of mAbs 1G8 and 3E6 with excess GST-fusion protein and by staining with secondary antibody alone, both of which showed no staining (data not shown) PSCA protein is expressed by a majority of localized prostate cancers and correlates with gleason score, pathologic stage and androgen-independence
In our previous study, PSCA mRNA was expressed in *80% of tumors and appeared to be expressed more highly in malignant than normal glands . In order to determine if PSCA protein can be detected in prostate cancers and if PSCA protein levels are increased in malignant compared with benign glands, 112 paran-embedded prostate cancer specimens were analysed by immunohistochemistry using mAb 1G8 (Figure 4 ). As described in Materials and methods, slides were assigned a composite score of 0 ± 9 based on the percentage of positive cells and staining intensity. One hundred and ®ve of 112 (94%) tumors stained positive for PSCA, of which 23 (21%) cancers stained very strongly for PSCA (i.e. nine) and another 70 (63%) had moderate staining (i.e. scores 3 ± 6) ( Table 2 ). The remaining 19 (17%) tumors were weakly positive (i.e. scores 1 ± 2; 11%) or negative (i.e. score 0; 6%). Using this semi-quantitative scoring method, the level of PSCA expression correlated signi®cantly with both Gleason score (P=0.016) and the pathologic tumor stage (P=0.008). Thirty-two per cent of Gleason 8 ± 10 cancers had very strong staining compared to only 11% with Gleason scores 5 ± 6. Likewise, 40% of locally advanced and node positive tumors (i.e. stages T3c-T4 and N+) expressed high levels of PSCA versus 15% that were organ con®ned or had extracapsular extension alone (i.e. T2-T3b) (Table 3) .
When PSCA immunostaining in the tumor was compared to that in adjacent normal glands, 40 (36%) tumors showed PSCA overexpression (i.e. expression in the tumor greater than normal). PSCA overexpression correlated with Gleason score (P=0.008). Forty-eight per cent of Gleason 8 ± 10 tumors overexpressed PSCA compared with only 22% Testis, endometrium, liver, gallbladder, pancreas, small intestine, bone marrow, thymus, spleen, lymph node, breast skeletal muscle, heart, brain, peripheral nerve, skin, lung, thyroid, adrenal *A minimum of two specimens from each tissue was examined Figure 3 Examples of PSCA immunostaining in extraprostatic normal tissues. Paran-embedded tissue specimens from placenta, bladder, colon and kidney were stained with anti-PSCA monoclonal antibodies. In the placenta, staining was seen in trophoblasts (arrow). In the bladder, staining was con®ned to the super®cial layer of transitional epithelium (arrow). Staining in the colon was seen in neuroendocrine cells (arrow) within colonic crypts and con®rmed by double-staining with chromogranin as shown (blue signi®es chromogranin and brown signi®es 1G8); no counterstain used). Staining in the kidney was seen in collecting ducts (arrow) and occasional distal tubules (note that endogenous biotin activity was blocked as described in Materials and methods)
of Gleason 5 ± 6 cancers (Table 2) . Interestingly, four of the six Gleason 5 ± 6 tumors with PSCA overexpression contained large foci of cribriform carcinoma, a subtype of prostate adenocarcinoma which has been associated with worse prognosis and a high frequency of genetic aberrations (McNeal et al., 1986; Qian et al., 1997; Rubin et al., 1998) . With regards to the pathologic stage, 48% of T3c-T4, N+ tumors overexpressed PSCA compared with 28% of localized cancers, although this did not reach statistical signi®cance (P=0.067; Table 3 ). Six specimens were obtained from patients treated prior to surgery with hormone ablation therapy. Five of six (83%) of these androgen-independent cancers overexpressed PSCA, compared with 33% of patients with androgendependent tumors (P=0.021). These results demonstrate that PSCA protein is expressed in a majority of cancers and that the level of PSCA expression (de®ned both semi-quantitatively and by comparison with adjacent normal glands) correlates with grade, stage and progression to androgenindependence.
Correlation of PSCA immunostaining and mRNA in situ hybridization
In 102 cases, we were able to compare the results of PSCA immunostaining with our previous mRNA in Prostate stem cell antigen expression Z Gu et al situ hybridization analysis (ISH) . Areas of positive immunostaining were identical to those seen by ISH in 92/102 (90.2%) specimens. Importantly, 12/15 cases with mRNA composite scores of 0 ± 4 also had PSCA protein expression scores of 0 ± 4. However, in 21 cases with mRNA expression scores 6 ± 9 there was less or absent protein expression (i.e. scores 0 ± 4), suggesting that PSCA may be modi®ed posttranscriptionally or that the epitopes recognized by the monoclonal antibodies may be obscured in some tumors.
PSCA protein is expressed strongly in prostate cancers metastatic to bone
Prostate cancer is unique among human tumors in its propensity to metastasize preferentially to bone and to induce osteoblastic responses. Nine sections of prostate cancer bone metastases were examined immunohistochemically ( Figure 5 ). All reacted intensely and uniformly (i.e. composite score of nine) with mAb 1G8. In two instances, micrometastases not readily detectable on hematoxylin and eosin sections could be seen after staining. In three cases, biopsy specimens from the primary tumors were available for comparison. All were weakly positive for PSCA when compared with the matched bone metastases, suggesting that PSCA expression was increased in bone. To rule out the possibility that the strong staining in bone was caused by the decalci®cation process used to prepare bone sections, the three primary biopsy specimens were also treated with decalci®cation buer. Although this treatment increased background staining, it did not alter epithelial reactivity signi®cantly, indicating that the strong signal in the bone was unlikely to be caused by the decalci®cation process (data not shown). These results demonstrate that PSCA is expressed strongly and may be upregulated in prostate cancer bone metastases.
Discussion
This study describes the ®rst characterization of PSCA protein expression using ®ve monoclonal antibodies directed against PSCA. PSCA mAbs stain the cell surface in a punctate manner, suggesting that PSCA may be localized to speci®c regions of the cell surface. GPI-anchored proteins are known to cluster in detergent-insoluble glycolipid-enriched microdomains (DIGS) of the cell surface (Varma and Mayor, 1998). These microdomains, which include caveolae and sphingolipid-cholesterol rafts, are believed to play critical roles in signal transduction and molecular transport (Anderson, 1993; Friedrichson and Kurzchalia, 1998; Hoessli and Robinson, 1998) . Thy-1, a homologue of PSCA, has previously been shown to transmit signals to src kinases through interaction in lipid-microdomains (Stefanova et al., 1991; Thomas and Samuelson, 1992; Xavier et al., 1998) . Additional studies will be needed to determine whether PSCA localizes preferentially in caveolae and/or cholesterol rafts and whether the mAbs described herein can transmit signals through PSCA analogous to those seen with Thy-1. Although PSCA mRNA localizes exclusively to basal cells, the current results suggest that PSCA protein may be present in both basal and secretory cells. Similar dierences between mRNA and protein localization in prostate have been described for p27, PSMA and androgen receptor (Cordon-Cardo et al., 1998; Kawakami and Nakayama, 1997; Magi-Galluzzi and Loda, 1996; Magi-Galuzzi et al., 1997) . One possible explanation for the presence of PSCA protein in secretory cells is that PSCA mRNA is transcribed in basal progenitor cells, but that PSCA protein expression persists as basal cells dierentiate into secretory cells. Another possibility is that PSCA protein may be transferred from basal to secretory cells posttransalationally. GPI-anchored proteins can incorporate into the plasma membranes of adjacent cells via their glycolipid anchors (Arienti et al., 1997) . Spermatozoa, for example, acquire GPI-anchored proteins from epithelial cells lining the epididymis (Arienti et al., 1997) . Finally, false-positive staining of secretory cells cannot be absolutely excluded. Additional studies will be necessary to understand fully the expression and natural history of PSCA in normal prostate epithelium.
Although largely prostate-speci®c in men, PSCA is also expressed in urothelium, colonic and gastric neuroendocrine cells and renal collecting ducts. The primary impetus for identifying prostate-speci®c cell surface genes is the desire to develop more selective, less toxic therapies. Expression of PSCA in advanced prostate tumors appears signi®cantly stronger than the staining seen in extraprostatic sites. Therapies directed against PSCA may therefore be relatively selective for cancer, much as Her-2/neu antibodies primarily target breast cancers which overexpress Her-2/neu (Disis and Cheever, 1997). Preclinical and clinical trials will be necessary to assess potential toxicity related to extraprostatic expression.
The present study supports our earlier observation that PSCA mRNA is overexpressed in a subset of prostate cancers . A new ®nding in the present study was the correlation of PSCA protein expression with tumor stage, grade and androgenindependence. Similar results were obtained regardless of whether we assessed absolute levels of PSCA expression semi-quantitatively (i.e. percentage of positive cells and staining intensity) or compared expression in tumor and normal glands. The association of PSCA overexpression with tumor stage and grade raises the possibility that PSCA may have diagnostic utility in prostate cancer. It will be particularly interesting to see if PSCA protein expression correlates with or can predict clinical outcome. Follow-up for our cohort was too short (i.e. mean follow-up *2 years with only two deaths) to provide meaningful survival ®gures.
In a number of instances, there was absent or weak immunostaining despite strong mRNA expression by in situ hybridization. Although it is possible that this may re¯ect posttranscriptional modi®cation of PSCA, it is likely that the epitopes recognized by the mAbs are hidden in some cancers by aberrant glycosylation. For example, we previously reported that the LAPC-4 xenograft tumor expresses large amounts of PSCA mRNA; however, none of the mAbs described in this study can recognize PSCA protein in LAPC-4 unless the tumor is deglycosylated prior to immunoblotting (R Reiter, unpublished result) .
The cause(s) of PSCA overexpression is not known. PSCA maps distal to c-myc on chromosome 8q24.2. Ampli®cation of c-myc correlates with locally advanced, cribriform, metastatic and androgen-independent cancers, similar to PSCA expression Kokontis et al., 1994; Qian et al., 1997) . Cmyc ampli®cation also correlates strongly with decreased survival from prostate cancer (Sato et al., 1999) . We have analysed a small number of locally advanced tumors with c-myc ampli®cation and found that PSCA is co-ampli®ed with c-myc (Reiter et al., 2000) . PSCA expression in these tumors was higher than in adjacent normal glands. PSCA overexpression may be a potential cell surface marker of aggressive tumors with c-myc ampli®cation.
One of the most intriguing results of the present study was the consistent, intense staining seen in the nine prostate cancer bone metastates. LAPC-9, a xenograft established from a bony metastasis, also stained intensely for PSCA. It is not known whether PSCA expression is up-regulated in bone, whether cells expressing high levels of PSCA may localize preferentially to bone, or whether PSCA expression simply re¯ects the advanced nature of these tumors and/or the presence of PSCA gene ampli®cation (Alers et al., 1997) . In three patients, matched primary biopsy specimens showed low levels of PSCA expression compared to the bony metastases, suggesting that PSCA expression may be upregulated. However, areas of strong PSCA expression in the primary tumors of the three patients examined may have been missed since only biopsies were available for analysis. Also, in two cases the primary tumor was sampled at least a decade prior to the bone metastasis, raising the possibility that clones expressing high levels of PSCA within the primary could have developed subsequent to the initial biopsy. Nevertheless, these results clearly demonstrate strong PSCA expression in bone metastases, further supporting it as a potentially novel diagnostic or therapeutic target for advanced disease.
Materials and methods

Generation and production of monoclonal antibodies
BALB/c mice were immunized three times with a puri®ed PSCA-glutathione S-transferase (GST) fusion protein containing PSCA amino acids 21 ± 99. Spleen cells were fused with HL-1 myeloma cells using standard hybridoma technique. Hybridomas that were positive for PSCA by ELISA and FACS analysis (see Results) were subcloned. Ascites¯uid was produced in CB 17 scid/scid mice and monoclonal antibodies (mAbs) puri®ed using a protein G anity column (Pharmacia Biotech, Piscataway, NJ, USA). PSCA mAb 1G8 was also produced in Cell-Pharm System 100 as recommended by the manufacturer (Unisyn Technologies, Hopkinton, MA, USA).
ELISA for hybridoma screening
GST or PSCA-GST were immobilized on Reacti-Bind maleic anhydride-activated polystyrene plates (Pierce, Rockford, IL, USA). Fifty ml of hybridoma media were added to each well and incubated for 1 h at room temperature. Wells were washed three times with 200 ml PBS containing 0.1% BSA and 0.05% Tween 20 and incubated for 1 h with 100 ml antimouse IgG (1 : 4000) labeled with alkaline phosphatase (Promega, Madison, WI, USA). Plates were developed with an alkaline phosphatase substrate (Bio-Rad, Hercules, CA, USA).
Cell culture
LNCaP was obtained from ATCC and stably transfected with a pCDNA II (Invitrogen) expression vector containing PSCA or vector alone . 293T cells transiently transfected with PSCA or vector alone were prepared as described previously . LAPC-9 xenograft explants were propagated in PrEGM media (Clonetics, San Diego, CA, USA) after digestion in 1% pronase for 18 min at room temperature (Whang et al., 1998) . Before FACS analysis, LAPC-9 cells were passed through a 40 mm cell strainer to obtain single cell suspensions.
Immunofluorescence
Cells were grown on glass coverslips coated with poly-Llysine. Immuno¯uorescence assays were carried out on permeabilized and nonpermeabilized ®xed cells. For ®xation, cells were treated with 2% paraformaldehyde in PBS-CM (PBS, 100 mM CaCl 2 , 1 mM MgCl 2 ) for 30 min in the dark, quenched with 50 mM NH 4 Cl in PBS-CM-BSA (PBS, 100 mM CaCl 2 , 1 mM MgCl 2 , 0.2% BSA) for 10 min, and washed twice with PBS-CM-BSA. For permeabilization, cells were treated additionally with PBS-CM-BSA-Saponin (0.075% saponin (Sigma) in PBS-CM-BSA) for 15 min at room temperature. Primary mAb at 2 ± 5 mg/ml in PBS-CM-BSA (plus saponin in cases of permeabilization) was added for 60 min and washed twice with PBS-CM-BSA. FITC-conjugated goat antimouse IgG antibody (1 : 500 diluted in PBS-CM-BSA +/7 saponin; Southern Biotechnology, Birmingham, AL, USA) was added for 30 min and washed three times with PBS-CM. Slides were mounted in vectashield (Vector Laboratory, Inc., Burlingame, CA, USA).
Flow cytometry
Cells (1610 6 ) were incubated for 30 min at 48C with 100 ml mAb at 2 mg/ml in PBS containing 2% fetal bovine serum or hybridoma conditioned medium. After washing, cells were stained with a 1 : 500 dilution of FITC-conjugated goat antimouse IgG (Southern Biotechnology, Birmingham, AL, USA). Data was acquired on a FACScan (Becton Dickinson) and analysed by using LYSIS II software.
Immunohistochemistry
Normal formalin-®xed, paran-embedded tissue samples were obtained from the Departments of Pathology at BethIsrael-Deaconess Medical Center and UCLA. Primary radical and transurethral prostatectomy specimens were selected from a previously described database (Magi-Galluzzi et al., 1997) . Bone metastases and matched primary biopsy specimens were obtained from the UCLA Department of Pathology. Normal tissues were stained and scored independently at two institutions in order to ensure reproducibility. Specimens obtained from UCLA were stained using modi®cations of an immunoperoxidase technique previously described . Antigen retrieval was performed on paran sections using a commercial steamer and 0.01 M citrate buer pH 6.0. After incubation with PSCA mAbs for 50 min (see below), slides were treated sequentially with rabbit anti-mouse IgG, swine anti-rabbit IgG and rabbit antiswine IgG, all biotin conjugated. Slides were then incubated with strepavidin-peroxidase and antibody localization performed using the diaminobenzidene reaction. All slides were stained with secondary antibody alone as a negative control. Speci®city of staining was also tested by incubating PSCA mAb with excess PSCA GST-fusion protein prior to staining. Specimens obtained from Beth-Israel-Deaconess Medical Center were stained as previously described using an automated Ventana NexES instrument (Ventana Medical Systems, Tucson, AZ, USA) (Magi-Galluzzi et al., 1997). Antigen retrieval was done by microwave for 15 min in EDTA, pH 8.05 at 750 W. mAbs puri®ed at a concentration of *1 mg/ml of SCID ascites were used at the following concentrations:
1G8=1 : 20; 3E6=1 : 30; 2H9=1 : 50; 4A10=1 : 100; 3C5=1 : 100. Endogenous biotin activity was blocked using Ventana AB block. mAb 1G8 was produced in CellPharm System 100 and used at concentrations of 1 : 10 or 1 : 20 depending on mAb titre. Positive controls included LAPC-9 and LNCaP-PSCA and negative controls were LNCaP and isotype matched irrelevant antibody. Primary biopsy specimens were available for three patients with bone metastases. To approximate conditions of decalci®cation, slides from these specimens were treated for 20 min in DecalStat (Lengers, NY, USA) prior to staining with PSCA mAbs.
Analysis of immunohistochemical staining
Slides of primary prostate tumors were read and scored by two pathologists (GV Thomas and M Loda) in a blinded fashion. There was greater than 90% inter-and intraobserver agreement. Scoring was done by two independent methods. The ®rst method of scoring quanti®ed the level of PSCA expression in tumors. Scores of 0 ± 3 were assigned according to the percentage of positive tumor cells (0=0%; 1=525%; 2=25 ± 50%; 3=450%) and the intensity of staining in tumor (0=0; 1=1+; 2=2+; 3=3+). The two scores were multiplied to give an overall score of 0 ± 9, of which 0 was considered negative, 1 ± 2 was considered weak, 3 ± 6 moderate and nine strong staining (Epstein et al., 1995; Hanas et al., 1999; Sauvageot and Epstein, 1998) . The mRNA in situ hybridizations reported previously were recorded in the same manner .
The second method of scoring examined the intensity of staining of tumor glands compared to adjacent normal glands. Here, the intensity of staining in greater than 50% of the tumor was compared to the intensity of staining in adjacent normal glands on the same slide. Staining in tumor was scored as being greater, equal or less than in adjacent normal glands. Staining which was greater in tumor than normal was taken as evidence of PSCA overexpression.
Statistics
Associations between PSCA expression and Gleason score, androgen dependence and pathologic stage were tested using the Kendall Tau Correlation method or Fisher's Exact Test as appropriate.
